• Aucun résultat trouvé

Inter-provider variation in resource use intensity for elderly injury admissions : a multicenter cohort study

N/A
N/A
Protected

Academic year: 2021

Partager "Inter-provider variation in resource use intensity for elderly injury admissions : a multicenter cohort study"

Copied!
80
0
0

Texte intégral

Loading

Figure

Table 1:  Resource use determinants for patient with trauma and fragility fractures.
Figure 1:  Relative effect size* (Cohen’s f 2 , %) of resource use determinants for trauma  (left) and fragility fractures (right)
Table 3:  Association between resource use and in-hospital mortality & complications
Figure 2:  Correlation of resource use and mortality and complications

Références

Documents relatifs

Dans la forme classique, la maladie débute par la survenue aigüe ou subaigüe de symptômes neurologiques multifocaux et d’une encéphalopathie souvent précédés d’une infection

In this study, we investigated the impact of growing sea- son length (triggered by natural snowmelt timing) and ele- vation on shrub growth and risk of exposure to potentially

Ce fils de sacristain entré au séminaire Par sa philosophie va changer les critères De quoi est fait le monde qui a pu le créer Pourquoi les choses existent quelle réalité Heidegger

In multivariate analysis, prehospital variables including minimum prehospital mean arterial pressure, maximum prehospital heart rate, secondary transfer to the trauma center and

Boxplots of community weighted mean of traits in living and dead testate amoeba assemblages in the Neuchâtel Botanic Garden experimental peatland (BG 2015, BG 2016) and

Indeed, it involves 4 different kernels (POTRF, TRSM, SYRK and GEMM) whose acceleration ratios on GPUs are strongly different (from 2.3 for POTRF to 29 for GEMM) and it consists in

Continuous observations of temperature and humidity in the crawl space are being recorded by means of a hygrothermograph and periodic visual checks will be made during the winter

The frontrunners in late-stage vaccine development, with reported interim analysis results of the vaccine being 95% effective in preventing COVID-19, is from the phase III